<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283801</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-119</org_study_id>
    <nct_id>NCT02283801</nct_id>
  </id_info>
  <brief_title>Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.</brief_title>
  <official_title>A Phase 1, Open-label Drug Interaction Study Between Eslicarbazepine Acetate 1200mg and Lamotrigine 150mg Following Multiple Doses Administrations in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, open-label, multiple doses, one-sequence design study in two parallel groups&#xD;
      of healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, open-label, multiple doses, one-sequence design study in two parallel groups&#xD;
      of healthy volunteers: Group A: Pre-treatment with ESL, treatment with ESL and ascending&#xD;
      doses of Lamotrigine (LMT) in last phases; Group B: Pre-treatment with LMT, treatment with&#xD;
      LMT and ascending doses of ESL in last phases&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - the maximum plasma concentration</measure>
    <time_frame>Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - the area under the plasma concentration-time curve from time zero to the last sampling time</measure>
    <time_frame>Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax - the time of occurrence of Cmax</measure>
    <time_frame>Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A&#xD;
Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;&#xD;
Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days&#xD;
Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days&#xD;
Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B&#xD;
Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;&#xD;
Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;&#xD;
Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days&#xD;
Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eslicarbazepine acetate</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>ESL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>LMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Availability of volunteer for the entire study period and willingness to adhere to&#xD;
             protocol requirements as evidenced by the informed consent form (ICF) duly read,&#xD;
             signed and dated by the volunteer&#xD;
&#xD;
          -  Male aged of at least 18 years but not older than 45 rears with a body mass Ã­ndex&#xD;
             (BMI) greater than or equal to 19 and below 30 kg/m&#xD;
&#xD;
          -  Clinical laboratory values within the laboratory's stated normal range; if not within&#xD;
             this range, they must be without any clinical significance (laboratory tests are&#xD;
             presented in section 6.1.1.3)&#xD;
&#xD;
          -  Healthy according to the medical history, laboratory results and physical examination&#xD;
&#xD;
          -  Light-, non- or ex-smokers. A light smoker is defined as someone smoking 1 0&#xD;
             cigarettes or less per day, and an ex-smoker is defined as someone who completely&#xD;
             stopped smoking for at least 12 months before day I of thi s study The informed&#xD;
             consent form must be signed by all volunteers, prior to their participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history of hypersensitivity to lamotrigine, eslicarbazepine,&#xD;
             oxcarbazepine, carbamazepine or any related products (including excipients of the&#xD;
             formulations) as well as severe hypersensitivity reactions (like angioedema) to any&#xD;
             drugs&#xD;
&#xD;
          -  Presence of significant gastrointestinal, liver or kidney disease, or any other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs or known to potentiate or predispose to undesired effects&#xD;
&#xD;
          -  History of significant gastrointestinal, liver or kidney disease, or surgery that may&#xD;
             affect drug bioavailability, including but not limited to cholecystectomy&#xD;
&#xD;
          -  Presence of significant cardiovascular, pulmonary, hematologic, neurologic,&#xD;
             psychiatric, endocrine, immunologic or dermatologic disease&#xD;
&#xD;
          -  Presence of significant heart disease or disorder according to ECG&#xD;
&#xD;
          -  Presence or history of significant central nervous system disorder like convulsion or&#xD;
             depression&#xD;
&#xD;
          -  Presence or history of significant ocular disease&#xD;
&#xD;
          -  Maintenance therapy with any drug, or significant history of drug dependency or&#xD;
             alcohol abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol, acute or&#xD;
             chronic).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 28, 2014</submitted>
    <returned>December 3, 2014</returned>
    <submitted>December 19, 2014</submitted>
    <returned>January 9, 2015</returned>
    <submitted>January 12, 2015</submitted>
    <returned>January 16, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

